Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Fragment-end sequence architecture of cell-free DNA and its association with tumour DNA in non-small cell lung cancer.

Created on 15 Nov 2026

Authors

Dhruv Das, Prachi Gupta, Rahul Tambade, P A Hassan, A V S S Narayana Rao, Rajani Kant Chittela

Published in

Clinical and translational medicine. Volume 16. Issue 11.

Abstract

Circulating cell-free DNA (cfDNA) fragmentation patterns provide a promising source of molecular information for liquid biopsy applications. However, the sequence features underlying fragmentation and their relationship to tumour-derived DNA remain incompletely understood. Here, we characterized fragment-end sequence signatures of extracellular cfDNA across cell lines, extracellular compartments, stress conditions and plasma from patients with non-small cell lung cancer (NSCLC).
cfDNA derived from cell lines was characterized using Oxford Nanopore sequencing, followed by fragment-end analysis. Publicly available Nanopore cfDNA datasets from healthy individuals and NSCLC patients were analyzed to examine dinucleotide patterns and derive a motif ratio index. These signatures were further assessed for their association with estimated ctDNA abundance in an independent cohort of 50 EGFR-mutant NSCLC patients.
Nanopore sequencing of A549, H460 and WI38 cell-line cfDNA revealed reproducible end-motif patterns, with enrichment of AT-, GT- and CT-containing termini. Analysis of plasma cfDNA from healthy individuals showed distinct end-motif profiles from cell-line-derived cfDNA, with separation maintained after reducing 4-mer motifs to 5'-terminal dinucleotide features. An exploratory motif ratio based on these patterns showed a modest increase in lung cancer patients compared with healthy individuals. In an independent Illumina cohort of 50 NSCLC patients with activating EGFR mutations, 5'-terminal dinucleotide frequencies were associated with estimated circulating tumour DNA (ctDNA) abundance using cross-validated LASSO (Least Absolute Shrinkage and Selection Operator) regression (Spearman ρ = .73, p = 3.35 × 10‒9). The predefined motif ratio showed a strong correlation with estimated ctDNA concentration (Spearman ρ = .76, p = 1.89 × 10‒10).
These findings suggest that simple, interpretable cfDNA end-motif signatures capture sequence features associated with ctDNA abundance and warrant further validation for non-invasive cancer monitoring.

PMID:
43034279
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement